Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside » 07:37
06/09/21
06/09
07:37
06/09/21
07:37
FSTX

F-star Therapeutics

$6.99 /

+0.06 (+0.87%)

B. Riley analyst Justin…

B. Riley analyst Justin Walsh last night initiated coverage of F-star Therapeutics with a Buy rating and $28 price target, which represents 307% potential upside from current levels. F-star is a clinical-stage immuno-oncology biotech company whose bispecific antibody platform has moved three assets into the clinic targeting unmet needs in the multi-billion-dollar solid tumor checkpoint inhibitor market, Walsh tells investors in a research note. The analyst sees the "steady cadence of data readouts" expected across F-star's clinical assets as providing the "potential fuel needed to further de-risk its platform and pipeline."

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.99 /

+0.06 (+0.87%)

FSTX F-star Therapeutics
$6.99 /

+0.06 (+0.87%)

06/08/21 B. Riley
F-star Therapeutics initiated with a Buy at B. Riley
04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
FSTX F-star Therapeutics
$6.99 /

+0.06 (+0.87%)

  • 09
    May
FSTX F-star Therapeutics
$6.99 /

+0.06 (+0.87%)

Initiation
F-star Therapeutics initiated with a Buy at B. Riley » 19:16
06/08/21
06/08
19:16
06/08/21
19:16
FSTX

F-star Therapeutics

$6.99 /

+0.06 (+0.87%)

B. Riley initiated…

B. Riley initiated coverage of F-star Therapeutics with a Buy rating and $28 price target.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.99 /

+0.06 (+0.87%)

FSTX F-star Therapeutics
$6.99 /

+0.06 (+0.87%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
FSTX F-star Therapeutics
$6.99 /

+0.06 (+0.87%)

  • 09
    May
FSTX F-star Therapeutics
$6.99 /

+0.06 (+0.87%)

Hot Stocks
Inivata, F-star Therapeutics collaborate for use of RaDaR assay » 07:06
05/25/21
05/25
07:06
05/25/21
07:06
FSTX

F-star Therapeutics

$8.16 /

+0.05 (+0.62%)

Inivata announced a…

Inivata announced a collaboration with F-star Therapeutics for the use of Inivata's RaDaR technology. Under the collaboration, Inivata's RaDaR technology, a personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity, will be applied to identify and evaluate potential early biomarkers of clinical efficacy.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$8.16 /

+0.05 (+0.62%)

FSTX F-star Therapeutics
$8.16 /

+0.05 (+0.62%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
FSTX F-star Therapeutics
$8.16 /

+0.05 (+0.62%)

  • 09
    May
FSTX F-star Therapeutics
$8.16 /

+0.05 (+0.62%)

Hot Stocks
F-star Therapeutics takes 5.7% passive stake in F-star Therapeutics » 16:41
05/18/21
05/18
16:41
05/18/21
16:41
FSTX

F-star Therapeutics

$6.89 /

+0.1 (+1.47%)

Point72 Asset Management…

Point72 Asset Management disclosed a 5.7% stake in F-star Therapeutics, which represents 1.1M shares. The filing does not allow for activism.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.89 /

+0.1 (+1.47%)

FSTX F-star Therapeutics
$6.89 /

+0.1 (+1.47%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
FSTX F-star Therapeutics
$6.89 /

+0.1 (+1.47%)

  • 09
    May
FSTX F-star Therapeutics
$6.89 /

+0.1 (+1.47%)

Over a month ago
Hot Stocks
F-star Therapeutics expects cash to fund operating plans into 2H23 » 08:15
05/17/21
05/17
08:15
05/17/21
08:15
FSTX

F-star Therapeutics

$6.58 /

-0.22 (-3.24%)

Cash and cash equivalents…

Cash and cash equivalents as of March 31, 2021 were $3.7 million, compared to $18.5 million at December 31, 2020. Based on the Company's current operating plan, the Company believes its cash and cash equivalents at March 31, 2021, together with the net proceeds from the recent sales of common stock in the underwritten public offering and under the ATM, and funds from its debt facility will be sufficient to fund its current operating plans into the second half of 2023.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.58 /

-0.22 (-3.24%)

FSTX F-star Therapeutics
$6.58 /

-0.22 (-3.24%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
FSTX F-star Therapeutics
$6.58 /

-0.22 (-3.24%)

  • 09
    May
FSTX F-star Therapeutics
$6.58 /

-0.22 (-3.24%)

Earnings
F-star Therapeutics reports Q1 EPS ($1.08), consensus ($1.16) » 08:14
05/17/21
05/17
08:14
05/17/21
08:14
FSTX

F-star Therapeutics

$6.58 /

-0.22 (-3.24%)

Reports Q1 revenue $2.9M,…

Reports Q1 revenue $2.9M, consensus $1.2M. Eliot Forster, CEO of F-star Therapeutics, Inc., said, "I'm very proud of what F-star accomplished in our first full quarter as a publicly traded company. The successful close of our public offering means we have now strengthened our financial position to ensure delivery on our future milestones. We have made excellent progress across all four clinical stage programs. We have also delivered with our partners, as noted in the recent update on our collaboration with Merck KGaA. We have added new insights into the unique properties of our platform technology, including presenting new data on FS222, our potentially best-in-class bispecific antibody targeting CD137 and PD-L1. This year will be another exciting one for F-star with clinical data expected and huge potential to provide transformational treatment options for patients with cancer."

ShowHide Related Items >><<
FSTX F-star Therapeutics
$6.58 /

-0.22 (-3.24%)

FSTX F-star Therapeutics
$6.58 /

-0.22 (-3.24%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
FSTX F-star Therapeutics
$6.58 /

-0.22 (-3.24%)

  • 09
    May
FSTX F-star Therapeutics
$6.58 /

-0.22 (-3.24%)

Syndicate
F-star Therapeutics 9.286M share Secondary priced at $7.00 » 08:02
05/07/21
05/07
08:02
05/07/21
08:02
FSTX

F-star Therapeutics

$8.73 /

-0.33 (-3.64%)

SVB Leerink acted as lead…

SVB Leerink acted as lead book running manager for the offering.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$8.73 /

-0.33 (-3.64%)

FSTX F-star Therapeutics
$8.73 /

-0.33 (-3.64%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
FSTX F-star Therapeutics
$8.73 /

-0.33 (-3.64%)

FSTX F-star Therapeutics
$8.73 /

-0.33 (-3.64%)

Syndicate
F-star Therapeutics announces common stock offering, no amount given » 16:53
05/06/21
05/06
16:53
05/06/21
16:53
FSTX

F-star Therapeutics

$8.73 /

-0.33 (-3.64%)

F-star Therapeutics…

F-star Therapeutics announced that it has commenced an underwritten public offering of its common stock. F-star intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for working capital and general corporate purposes, including, but not limited to, clinical trials, research and development activities and capital expenditures. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. SVB Leerink is acting as sole bookrunning manager for the offering.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$8.73 /

-0.33 (-3.64%)

FSTX F-star Therapeutics
$8.73 /

-0.33 (-3.64%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
FSTX F-star Therapeutics
$8.73 /

-0.33 (-3.64%)

FSTX F-star Therapeutics
$8.73 /

-0.33 (-3.64%)

Options
new option listings and three option delistings on April 21st » 08:30
04/21/21
04/21
08:30
04/21/21
08:30
APP

AppLovin

$60.40 /

+1.71 (+2.91%)

, BSPE

Bespoke Capital Acquisition

$10.08 /

+0.09 (+0.90%)

, CFB

CrossFirst Bancshares

$13.38 /

-0.27 (-1.98%)

, CHRA

Charah Solutions

$5.67 /

-0.47 (-7.65%)

, CTEC

Cholestech

$19.97 /

-0.63 (-3.06%)

, CYCC

Cyclacel Pharmaceuticals

$6.40 /

-0.11 (-1.69%)

, DFNS

LGL Systems Acquisition Corp.

$9.90 /

-0.04 (-0.40%)

, FARM

Farmer Bros.

$9.98 /

-0.29 (-2.82%)

, FSTX

F-star Therapeutics

$9.48 /

-0.28 (-2.87%)

, GENI

Genius Sports

$16.23 /

-2.025 (-11.09%)

, GNPK

Genesis Park Acquisition

$10.13 /

-0.06 (-0.59%)

, IDEV

Indevus

$66.33 /

-1.07 (-1.59%)

, INFU

InfuSystem

$21.63 /

-0.17 (-0.78%)

, JOAN

Joann

$11.37 /

-0.02 (-0.18%)

, MAX

MediaAlpha

$32.98 /

-1.76 (-5.07%)

, NVVE

Nuvve Holding

$8.59 /

-0.47 (-5.19%)

, OBLG

Oblong

$4.14 /

-0.19 (-4.39%)

, PSI

PSI Technologies Holdings, Inc.

$119.80 /

-2 (-1.64%)

, SCPH

scPharmaceuticals

$6.28 /

-0.13 (-2.03%)

, SMIN

Southern Mineral Corp

$45.90 /

-0.545 (-1.17%)

, SNSR

Control Devices

$33.59 /

-0.7 (-2.04%)

, WKEY

WISeKey

$8.45 /

-0.28 (-3.21%)

, XFOR

X4 Pharmaceuticals

$9.00 /

-0.3 (-3.23%)

, ZKIN

ZK International Group

$5.32 /

-0.19 (-3.45%)

, CBPO

China Biologic

$119.98 /

+2.2 (+1.87%)

, DMYD

dMY Technology II

/

+

, IPHI

Inphi

$172.33 /

-1.85 (-1.06%)

New option listings for…

New option listings for April 21st include First Trust RBA American Industrial Renaissance (AIRR), Applovin Corporation (Class A Stock) (APP), Bespoke Capital Acquisition Corporation (Class A Stock) (BSPE), CrossFirst Bankshares Inc (CFB), Charah Solutions Inc (CHRA), Global X CleanTech ETF (CTEC), Cyclacel Pharmaceuticals (CYCC), LGL Systems Acquisition Corp (Class A Stock) (DFNS), iShares Emerging Markets Dividend (DVYE), iShares MSCI Emerging Markets Asia (EEMA), Farmer Bros. (FARM), F star Therapeutics Inc (FSTX), First Trust Nasdaq Oil and Gas (FTXN), First Trust Nasdaq Bank (FTXO), First Trust Nasdaq Transportation (FTXR), First Trust Small Cap Core AlphaDEX Fund (FYX), Genius Sports Limited (GENI), Genesis Park Acquisition Corp (Class A Stock) (GNPK), iShares Core MSCI International Developed Markets ETF (IDEV), InfuSystem (INFU), iShares Russell Top 200 Growth (IWY), iShares US Consumer Services (IYC), iShares US Consumer Goods (IYK), JOANN Inc (JOAN), MediaAlpha Inc (Class A Stock) (MAX), Nuvve Holding Corporation (NVVE), Oblong Inc (OBLG), PowerShares Dynamic Semiconductors Portfolio (PSI), scPharmaceuticals Inc (SCPH), iShares MSCI India Small Cap ETF (SMIN), Global X Internet of Things Thematic (SNSR), Soaring Eagle Acquisition Corporation (Units) (SRNGU), iShares Core US REIT ETF (USRT), Vanguard International Dividend Appreciation ETN (VIGI), WISeKey International Holdings SA (ADR) (WKEY), X4 Pharmaceuticals Inc (XFOR), and ZK International Group Co Ltd (ZKIN). Option delistings effective April 21st include China Bioligic Products Holdings Inc (CBPO), dMY Technology Group Inc II (Class A Stock) (DMYD), and Inphi Corporation (IPHI).

ShowHide Related Items >><<
ZKIN ZK International Group
$5.32 /

-0.19 (-3.45%)

XFOR X4 Pharmaceuticals
$9.00 /

-0.3 (-3.23%)

WKEY WISeKey
$8.45 /

-0.28 (-3.21%)

SCPH scPharmaceuticals
$6.28 /

-0.13 (-2.03%)

OBLG Oblong
$4.14 /

-0.19 (-4.39%)

MAX MediaAlpha
$32.98 /

-1.76 (-5.07%)

JOAN Joann
$11.37 /

-0.02 (-0.18%)

IPHI Inphi
$172.33 /

-1.85 (-1.06%)

INFU InfuSystem
$21.63 /

-0.17 (-0.78%)

FSTX F-star Therapeutics
$9.48 /

-0.28 (-2.87%)

FARM Farmer Bros.
$9.98 /

-0.29 (-2.82%)

DMYD dMY Technology II
/

+

DFNS LGL Systems Acquisition Corp.
$9.90 /

-0.04 (-0.40%)

CYCC Cyclacel Pharmaceuticals
$6.40 /

-0.11 (-1.69%)

CHRA Charah Solutions
$5.67 /

-0.47 (-7.65%)

CFB CrossFirst Bancshares
$13.38 /

-0.27 (-1.98%)

CBPO China Biologic
$119.98 /

+2.2 (+1.87%)

APP AppLovin
$60.40 /

+1.71 (+2.91%)

BSPE Bespoke Capital Acquisition
$10.08 /

+0.09 (+0.90%)

04/21/21 Telsey Advisory
Bespoke Capital Acquisition initiated with an Outperform at Telsey Advisory
04/21/21 Telsey Advisory
Bespoke Capital Acquisition initiated with an Outperform at Telsey Advisory
CFB CrossFirst Bancshares
$13.38 /

-0.27 (-1.98%)

03/08/21 Truist
CrossFirst Bancshares price target raised to $15 from $12 at Truist
12/07/20 Raymond James
CrossFirst Bancshares upgraded to Outperform from Market Perform at Raymond James
12/07/20 Raymond James
CrossFirst upgraded to Outperform from Market Perform at Raymond James
07/20/20 Truist
CrossFirst Bancshares initiated with a Hold at SunTrust
CHRA Charah Solutions
$5.67 /

-0.47 (-7.65%)

CTEC Cholestech
$19.97 /

-0.63 (-3.06%)

CYCC Cyclacel Pharmaceuticals
$6.40 /

-0.11 (-1.69%)

05/19/20 Brookline
Cyclacel Pharmaceuticals initiated with a Buy at Brookline
04/27/20
Fly Intel: Top five analyst initiations
04/27/20 Roth Capital
Cyclacel Pharmaceuticals assumed with a Buy at Roth Capital
DFNS LGL Systems Acquisition Corp.
$9.90 /

-0.04 (-0.40%)

FARM Farmer Bros.
$9.98 /

-0.29 (-2.82%)

03/31/21 B. Riley
B. Riley upgrades Farmer Bros. to Buy with recovery 'turning a corner'
03/31/21 B. Riley
Farmer Bros. upgraded to Buy from Neutral at B. Riley Securities
02/08/21 Roth Capital
Farmer Bros. price target raised to $7 from $6 at Roth Capital
01/08/21 B. Riley
Farmer Bros. price target raised to $4.50 from $4 at B. Riley Securities
FSTX F-star Therapeutics
$9.48 /

-0.28 (-2.87%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
GENI Genius Sports
$16.23 /

-2.025 (-11.09%)

02/23/21 Benchmark
dMY Technology II initiated with a Buy at Benchmark
GNPK Genesis Park Acquisition
$10.13 /

-0.06 (-0.59%)

IDEV Indevus
$66.33 /

-1.07 (-1.59%)

INFU InfuSystem
$21.63 /

-0.17 (-0.78%)

12/29/20 Sidoti
InfuSystem initiated with a Buy at Sidoti
08/31/20
Fly Intel: Top five analyst initiations
08/31/20 Craig-Hallum
InfuSystem initiated with a Buy at Craig-Hallum
06/09/20 Lake Street
InfuSystem initiated with a Buy at Lake Street
JOAN Joann
$11.37 /

-0.02 (-0.18%)

04/06/21 William Blair
Joann initiated with an Outperform at William Blair
04/06/21 BofA
BofA starts Joann at Buy with $27 price target
04/06/21 Wells Fargo
Joann initiated with an Overweight at Wells Fargo
04/06/21 Guggenheim
Joann initiated with a Buy at Guggenheim
MAX MediaAlpha
$32.98 /

-1.76 (-5.07%)

03/12/21 Canaccord
MediaAlpha price target raised to $75 from $54 at Canaccord
03/12/21 RBC Capital
MediaAlpha price target raised to $65 from $50 at RBC Capital
12/11/20 Canaccord
MediaAlpha expected to be part of any insurance marketing, says Canaccord
12/08/20
Fly Intel: Top five analyst initiations
NVVE Nuvve Holding
$8.59 /

-0.47 (-5.19%)

04/19/21 Craig-Hallum
Nuvve Holding initiated with a Buy at Craig-Hallum
OBLG Oblong
$4.14 /

-0.19 (-4.39%)

PSI PSI Technologies Holdings, Inc.
$119.80 /

-2 (-1.64%)

SCPH scPharmaceuticals
$6.28 /

-0.13 (-2.03%)

12/08/20 BMO Capital
scPharmaceuticals price target lowered to $10 from $13 at BMO Capital
05/13/20 SVB Leerink
scPharmaceuticals price target raised to $12 from $7 at SVB Leerink
05/13/20 H.C. Wainwright
scPharmaceuticals price target raised to $15 from $13 at H.C. Wainwright
SMIN Southern Mineral Corp
$45.90 /

-0.545 (-1.17%)

SNSR Control Devices
$33.59 /

-0.7 (-2.04%)

WKEY WISeKey
$8.45 /

-0.28 (-3.21%)

09/09/20 H.C. Wainwright
WISeKey price target raised to $9 from $6 at H.C. Wainwright
XFOR X4 Pharmaceuticals
$9.00 /

-0.3 (-3.23%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
ZKIN ZK International Group
$5.32 /

-0.19 (-3.45%)

CBPO China Biologic
$119.98 /

+2.2 (+1.87%)

DMYD dMY Technology II
/

+

04/07/21 Craig-Hallum
Craig-Hallum sees Genius as 'a clear winner' after NY online sports betting news
04/05/21 Craig-Hallum
Genius Sports price target raised to $30 from $25 at Craig-Hallum
02/25/21 B. Riley
B. Riley starts dMY at Buy as better way to invest in sports betting
02/24/21 B. Riley
dMY Technology II initiated with a Buy at B. Riley Securities
IPHI Inphi
$172.33 /

-1.85 (-1.06%)

03/24/21 Stifel
Chinese approval for Inphi deal 'highly favorable' for Marvell, says Stifel
02/16/21 Needham
Inphi price target raised to $191 from $175 at Needham
02/09/21 Barclays
Inphi downgraded to Equal Weight on Marvell deal at Barclays
02/09/21 Barclays
Inphi downgraded to Equal Weight from Overweight at Barclays
XFOR X4 Pharmaceuticals
$9.00 /

-0.3 (-3.23%)

SCPH scPharmaceuticals
$6.28 /

-0.13 (-2.03%)

MAX MediaAlpha
$32.98 /

-1.76 (-5.07%)

JOAN Joann
$11.37 /

-0.02 (-0.18%)

IPHI Inphi
$172.33 /

-1.85 (-1.06%)

INFU InfuSystem
$21.63 /

-0.17 (-0.78%)

FSTX F-star Therapeutics
$9.48 /

-0.28 (-2.87%)

FARM Farmer Bros.
$9.98 /

-0.29 (-2.82%)

CYCC Cyclacel Pharmaceuticals
$6.40 /

-0.11 (-1.69%)

CFB CrossFirst Bancshares
$13.38 /

-0.27 (-1.98%)

CBPO China Biologic
$119.98 /

+2.2 (+1.87%)

  • 15
    Apr
  • 19
    Mar
  • 12
    Mar
  • 12
    Mar
  • 28
    Oct
  • 21
    May
IPHI Inphi
$172.33 /

-1.85 (-1.06%)

DMYD dMY Technology II
/

+

MAX MediaAlpha
$32.98 /

-1.76 (-5.07%)

JOAN Joann
$11.37 /

-0.02 (-0.18%)

IPHI Inphi
$172.33 /

-1.85 (-1.06%)

GNPK Genesis Park Acquisition
$10.13 /

-0.06 (-0.59%)

GENI Genius Sports
$16.23 /

-2.025 (-11.09%)

FARM Farmer Bros.
$9.98 /

-0.29 (-2.82%)

DMYD dMY Technology II
/

+

DFNS LGL Systems Acquisition Corp.
$9.90 /

-0.04 (-0.40%)

APP AppLovin
$60.40 /

+1.71 (+2.91%)

DMYD dMY Technology II
/

+

Hot Stocks
F-star Therapeutics announces publication of study on SB 11285 » 09:30
04/19/21
04/19
09:30
04/19/21
09:30
FSTX

F-star Therapeutics

$10.14 /

+0.765 (+8.16%)

F-star Therapeutics…

F-star Therapeutics announced the publication of a new study, conducted by Yale University and F-star, of its second generation STING agonist, SB 11285, in the current issue of Nature Communications. The study entitled "STING enhances cell death through regulation of reactive oxygen species and DNA damage" demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model enhances local control in Head and Neck Squamous Cell Carcinoma and suggests that STING expression in the tumor is required for maximal therapeutic benefit. Resistance to DNA-damaging agents such as radiation is a significant cause of treatment failure and poor outcomes in oncology. To identify unrecognized regulators of cell survival, the researchers performed a whole-genome CRISPR-Cas9 screen following treatment with ionizing radiation and identified STING as an intrinsic regulator of tumor cell survival. In addition, the study showed that STING overexpression restored tumor cell sensitivity to ionizing radiation and that STING loss confers resistance to DNA damaging therapies. Analysis of tumors from HNSCC patient specimens showed that low STING expression is associated with poor outcomes. The research also demonstrated that pharmacologic activation of STING enhances the effects of ionizing radiation in vivo, providing a rationale for therapeutic combinations of STING agonists and DNA-damaging agents as well as a strong rationale for investigating STING expression as a predictive biomarker.

ShowHide Related Items >><<
FSTX F-star Therapeutics
$10.14 /

+0.765 (+8.16%)

FSTX F-star Therapeutics
$10.14 /

+0.765 (+8.16%)

04/15/21 Oppenheimer
Opco starts F-star Therapeutics with Outperform, $30 price target
04/15/21 Oppenheimer
F-star Therapeutics initiated with an Outperform at Oppenheimer
04/08/21 William Blair
F-star Therapeutics initiated with an Outperform at William Blair
03/24/21
Fly Intel: Top five analyst initiations
FSTX F-star Therapeutics
$10.14 /

+0.765 (+8.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.